he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
82.5% of patients treated at 10mg dose of obicetrapib achieved LDL-c target of <70 mg/dL, compared to 20% of patients treated with placebo
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Dr. Bernstein will tap into her decades of leadership and strategy experience as she transitions into this new role at APhA
The information center has been established with the aim of providing Fortis Healthcare’s world-class healthcare services accessible to the people of Tirupati.
Norliqva was approved by the FDA on February 24, 2022 and is now available through normal retail distribution.
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025
Bempedoic acid helps lower cardiovascular risk in high or very high-risk atherosclerotic cardiovascular disease (ASCVD) patients as an add-on therapy to maximally tolerated statin and/or ezetimibe
Subscribe To Our Newsletter & Stay Updated
